Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.
Int J Mol Sci
; 23(12)2022 Jun 14.
Article
in English
| MEDLINE | ID: covidwho-1911400
ABSTRACT
The new SARS-CoV-2 coronavirus is responsible for the COVID-19 pandemic. A massive vaccination campaign, which is still ongoing, has averted most serious consequences worldwide; however, lines of research are continuing to identify the best drug therapies to treat COVID-19 infection. SARS-CoV-2 penetrates the cells of the host organism through ACE2. The ACE2 protein plays a key role in the renin-angiotensin system (RAS) and undergoes changes in expression during different stages of COVID-19 infection. It appears that an unregulated RAS is responsible for the severe lung damage that occurs in some cases of COVID-19. Pharmacologically modifying the expression of ACE2 could be an interesting line of research to follow in order to avoid the severe complications of COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Ijms23126644
Similar
MEDLINE
...
LILACS
LIS